Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Boule Diagnostics AB's Price-to-Tangible-Book or its related term are showing as below:
CHIX:BOULs'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.43 Med: 8.02 Max: 25.73
Current: 1.43
During the past 13 years, Boule Diagnostics AB's highest Price to Tangible Book Ratio was 25.73. The lowest was 1.43. And the median was 8.02.
CHIX:BOULs's Price-to-Tangible-Book is ranked better than 73.22% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 2.635
vs CHIX:BOULs: 1.43
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Boule Diagnostics AB Price-to-Tangible-Book Related Terms
Boule Diagnostics AB Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Boule Diagnostics AB (CHIX:BOULS) has a Price-to-Tangible-Book of 11.86 as of Sep. 05, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Boule Diagnostics AB and its competitors. According to the industry distribution chart, Boule Diagnostics AB ranks #188 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Boule Diagnostics AB's Price-to-Tangible-Book too high?
Boule Diagnostics AB's current Price-to-Tangible-Book is 11.86. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.64. Boule Diagnostics AB's value of 11.86 is 350.1% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #188 out of 702 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Boule Diagnostics AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #188 out of 702 companies for Price-to-Tangible-Book. This puts Boule Diagnostics AB in the upper half of its industry. The industry median Price-to-Tangible-Book is 2.64. Boule Diagnostics AB's value of 11.86 is 350.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.64, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Price-to-Tangible-Book of 11.86 is 350.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Price-to-Tangible-Book is 11.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Price-to-Tangible-Book of 11.86. The stock's GF Value™ is kr53.01, compared to a current price of kr26.30 — trading 50.4% below its estimated fair value. The current Price-to-Tangible-Book is 11.86 and 350.1% above the Medical Devices & Instruments industry median of 2.64. Boule Diagnostics AB's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Price-to-Tangible-Book is 11.86 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 50.4% below its estimated GF Value™ of kr53.01.
Key valuation signals for CHIX:BOULS:
Price-to-Tangible-Book: 11.86
GF Value™: kr53.01 vs. price of kr26.30 (50.4% below fair value)
Industry Position: 350.1% above the Medical Devices & Instruments median (#188 of 702)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
41GF Score
Get the complete analysis for CHIX:BOULS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
